High frequency of HIV precursor-target-specific B cells in sub-Saharan populations.

B cell CP: Immunology CP: Microbiology HIV vaccine

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
28 Nov 2023
Historique:
received: 05 06 2023
revised: 11 10 2023
accepted: 01 11 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: aheadofprint

Résumé

HIV gp120 engineered outer domain germline-targeting version 8 (eOD-GT8) was designed specifically to engage naive B cell precursors of VRC01-class antibodies. However, the frequency and affinity of naive B cell precursors able to recognize eOD-GT8 have been evaluated only in U.S. populations. HIV infection is disproportionally concentrated in sub-Saharan Africa, so we seek to characterize naive B cells able to recognize eOD-GT8 in sub-Saharan cohorts. We demonstrate that people from sub-Saharan Africa have a higher or equivalent frequency of naive B cells able to engage eOD-GT8 compared with people from the U.S. Genetically, the higher frequency of eOD-GT8-positive cells is accompanied by a higher level of naive B cells with gene signatures characteristic of the VRC01 class, as well as other CD4bs-directed antibodies. Our study demonstrates that vaccination with eOD-GT8 in sub-Saharan Africa could be successful at expanding and establishing a pool of CD4bs-directed memory B cells from naive precursors.

Identifiants

pubmed: 38019653
pii: S2211-1247(23)01462-6
doi: 10.1016/j.celrep.2023.113450
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113450

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests. This work was supported by a cooperative agreement (W81XWH-18-2-0040) between the Henry M. Jackson Foundation (HJF) for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD). This research was funded, in part, by the National Institute of Allergy and Infectious Diseases. The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army, the DOD, or the HJF. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70-25.

Auteurs

Flavio Matassoli (F)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: flavio.matassoli@nih.gov.

Alberto Cagigi (A)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Chen-Hsiang Shen (CH)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Amy R Henry (AR)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Timothy S Johnston (TS)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Chaim A Schramm (CA)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Christopher A Cottrell (CA)

Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.

Oleksandr Kalyuzhniy (O)

Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.

Abby Spangler (A)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Leigh Eller (L)

U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Merlin Robb (M)

U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Michael Eller (M)

U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Prossy Naluyima (P)

Makerere University Walter Reed Project, Kampala, Uganda.

Peter D Kwong (PD)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.

Daniel C Douek (DC)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

William R Schief (WR)

Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.

Sarah F Andrews (SF)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: sarah.andrews2@nih.gov.

Adrian B McDermott (AB)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Classifications MeSH